[Hyperkalemia in very low birthweight infants: incidence and associated factors]

P J Nader1, R S Procianoy

  • 1Universidade Federal do Rio Grande do Sul.

Insights

Hyperkalemia affects 38.5% of premature infants. Higher aldosterone levels were observed in infants with hyperkalemia, but other factors were not responsible. Careful serum potassium monitoring is crucial for these newborns.

Area of Science:

  • Neonatalogy
  • Pediatric Nephrology
  • Clinical Chemistry

Context:

  • Premature infants, particularly those with very low birthweight (
  • Hyperkalemia (serum potassium >or= 6 mEq/l) is a significant concern in the neonatal intensive care unit, with potential for cardiac complications.

Purpose:

  • To evaluate the incidence and potential contributing factors of hyperkalemia in very low birthweight premature infants within the first 72 hours of life.
  • To compare clinical and biochemical parameters between premature infants with and without hyperkalemia.

Summary:

  • The study observed a 38.5% incidence of hyperkalemia in premature infants (
  • Infants with hyperkalemia showed significantly lower gestational age and Apgar scores but similar birthweights compared to controls.
  • Despite similar management, hyperkalemic infants had higher aldosterone levels, yet no specific factor was identified as the sole cause of non-oliguric hyperkalemia.

Impact:

  • Highlights the high prevalence of hyperkalemia in a vulnerable neonatal population.
  • Suggests that current management strategies may not fully prevent hyperkalemia in very low birthweight infants.
  • Underscores the critical need for vigilant serum potassium monitoring and further research into the etiology of neonatal hyperkalemia.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...